98 related articles for article (PubMed ID: 1601678)
1. [Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Beck A; Maurer J; Welkoborsky HJ; Mann W
HNO; 1992 Apr; 40(4):123-7. PubMed ID: 1601678
[TBL] [Abstract][Full Text] [Related]
2. [Early detection of cisplatin-induced ototoxicity using evoked otoacoustic emissions].
Plinkert PK; Kröber S
Laryngorhinootologie; 1991 Sep; 70(9):457-62. PubMed ID: 1930486
[TBL] [Abstract][Full Text] [Related]
3. The effect of treatment with vincristine on transient evoked and distortion product otoacoustic emissions.
Riga M; Psarommatis I; Korres S; Lyra Ch; Papadeas E; Varvutsi M; Ferekidis E; Apostolopoulos N
Int J Pediatr Otorhinolaryngol; 2006 Jun; 70(6):1003-8. PubMed ID: 16359737
[TBL] [Abstract][Full Text] [Related]
4. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
5. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity.
Hotz MA; Harris FP; Probst R
Laryngoscope; 1994 Sep; 104(9):1130-4. PubMed ID: 8072361
[TBL] [Abstract][Full Text] [Related]
6. Effect of high-dose cisplatin on auditory brainstem responses and otoacoustic emissions in laboratory animals.
Sockalingam R; Freeman S; Cherny TL; Sohmer H
Am J Otol; 2000 Jul; 21(4):521-7. PubMed ID: 10912698
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
8. [Correlation between auditory threshold and transitory evoked otoacoustic emissions].
Komazec Z; Milosević D; Mocko M; Dankuc D; Vlaski L
Srp Arh Celok Lek; 2002; 130 Suppl 1():8-11. PubMed ID: 12395455
[TBL] [Abstract][Full Text] [Related]
9. Transient-evoked otoacoustic emissions in a group of professional singers who have normal pure-tone hearing thresholds.
Hamdan AL; Abouchacra KS; Zeki Al Hazzouri AG; Zaytoun G
Ear Hear; 2008 Jun; 29(3):360-77. PubMed ID: 18382377
[TBL] [Abstract][Full Text] [Related]
10. [Changes in otoacoustic emissions with simultaneous acoustic stimulation of the contralateral ear in normal probands and patients with unilateral acoustic neurinoma].
Maurer J; Beck A; Mann W; Mintert R
Laryngorhinootologie; 1992 Feb; 71(2):69-73. PubMed ID: 1571057
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions.
Hatzopoulos S; Di Stefano M; Campbell KC; Falgione D; Ricci D; Rosignoli M; Finesso M; Albertin A; Previati M; Capitani S; Martini A
Audiology; 2001; 40(5):253-64. PubMed ID: 11688544
[TBL] [Abstract][Full Text] [Related]
12. Left-right asymmetry in hearing loss following cisplatin therapy in children--the left ear is slightly but significantly more affected.
Schmidt CM; Knief A; Lagosch AK; Deuster D; am Zehnhoff-Dinnesen A
Ear Hear; 2008 Dec; 29(6):830-7. PubMed ID: 18772725
[TBL] [Abstract][Full Text] [Related]
13. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
14. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy.
Allen GC; Tiu C; Koike K; Ritchey AK; Kurs-Lasky M; Wax MK
Otolaryngol Head Neck Surg; 1998 May; 118(5):584-8. PubMed ID: 9591854
[TBL] [Abstract][Full Text] [Related]
15. Subclinical dysfunction of cochlea and cochlear efferents in migraine: an otoacoustic emission study.
Bolay H; Bayazit YA; Gündüz B; Ugur AK; Akçali D; Altunyay S; Ilica S; Babacan A
Cephalalgia; 2008 Apr; 28(4):309-17. PubMed ID: 18279433
[TBL] [Abstract][Full Text] [Related]
16. [Cisplatin ototoxicity. A clinical study].
Schröder M; Laskawi R; Stennert E; Kühnle H; Thiele FW
Laryngol Rhinol Otol (Stuttg); 1986 Feb; 65(2):86-9. PubMed ID: 3959692
[TBL] [Abstract][Full Text] [Related]
17. Distortion-product otoacoustic emissions and cochlear microphonics: relationships in patients with and without endolymphatic hydrops.
Fetterman BL
Laryngoscope; 2001 Jun; 111(6):946-54. PubMed ID: 11404602
[TBL] [Abstract][Full Text] [Related]
18. [Transitory evoked otoacoustic emissions in isolated high frequency, low frequency and middle frequency hearing].
Mathis A; De Min N; Arnold W
HNO; 1991 Feb; 39(2):55-60. PubMed ID: 2032875
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas.
Fety R; Rolland F; Barberi-Heyob M; Hardouin A; Campion L; Conroy T; Merlin JL; Rivière A; Perrocheau G; Etienne MC; Milano G
Clin Cancer Res; 1998 Sep; 4(9):2039-45. PubMed ID: 9748117
[TBL] [Abstract][Full Text] [Related]
20. Hearing loss in children with brain tumors treated with cisplatin and carboplatin-based high-dose chemotherapy with autologous bone marrow rescue.
Freilich RJ; Kraus DH; Budnick AS; Bayer LA; Finlay JL
Med Pediatr Oncol; 1996 Feb; 26(2):95-100. PubMed ID: 8531860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
